Show simple item record

dc.contributor.authorArababadi, Mohammad Kazemien_US
dc.contributor.authorMosavi, Rezaen_US
dc.contributor.authorKhoramdel, Hosseinen_US
dc.contributor.authorYaghini, Nargesen_US
dc.contributor.authorZarandi, Ebrahim Rezazadehen_US
dc.contributor.authorAraste, Majiden_US
dc.contributor.authorPourali, Rezaen_US
dc.contributor.authorNekhei, Zohreen_US
dc.contributor.authorKennedy, Dereken_US
dc.date.accessioned2017-05-03T11:12:28Z
dc.date.available2017-05-03T11:12:28Z
dc.date.issued2010en_US
dc.date.modified2011-10-06T04:59:12Z
dc.identifier.issn17520363en_US
dc.identifier.doi10.2217/BMM.10.81en_AU
dc.identifier.urihttp://hdl.handle.net/10072/34904
dc.description.abstractBackground and aim: Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This project aimed to evaluate the serum levels of relevant cytokines after therapy with IFN-? formulations in MS patients. Material and methods: In this study, blood samples were collected from 70 MS patients undergoing four different types of IFN-? formulation treatment and 100 healthy controls. After 24 months of treatment the serum levels of IL-17A, IL-12 and IFN-g and IL-10 in patients and healthy controls were analyzed by ELISA. Finding: Our results showed that serum levels of IL-17A were significantly higher in patients treated with Cinnovex and Anovex when compared to healthy controls. Serum levels of IL-10 were significantly decreased after therapy with Cinnovex, whereas serum levels of IFN-? were elevated. No difference in serum levels of IL-12 were detected in patients and controls. Conclusion: Results of our study suggest that Cinnovex and Anovex modulate the immune system less than Rebif and Betaferon in MS patients and that an elevated dosage/regime of Cinnovex and Anovex may be required for better regulation of the immune system in MS patients.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.format.extent90805 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherFuture Medicineen_US
dc.publisher.placeUnited Kingdomen_US
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom755en_US
dc.relation.ispartofpageto759en_US
dc.relation.ispartofissue5en_US
dc.relation.ispartofjournalBiomarkers in Medicineen_US
dc.relation.ispartofvolume4en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchMedical Genetics (excl. Cancer Genetics)en_US
dc.subject.fieldofresearchcode110311en_US
dc.titleCytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing–remitting multiple sclerosis in Iranian patientsen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.rights.copyrightCopyright 2010 Future Medicine Ltd. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal website for access to the definitive, published version.en_AU
gro.date.issued2010
gro.hasfulltextFull Text


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record